Transparency Market Research reveals in a recently released market
intelligence report that leading players from the global
cryptococcosis market are likely to participate in a wave of mergers
and acquisitions in all key regions of the market over the coming
years. Business conglomerates have significant investments in the
recent past to bring to fruition their research and development
efforts for new drugs and are interested in expanding their
distribution chain to broader regions. The global cryptococcosis
market was calculated to reach US$4.31 bn by the end of 2016, and is
projected to reach US$6.2 bn by the end of 2024, after expanding at a
CAGR of 4.8% from 2016 to 2024.
Report Overview @
https://www.transparencymarketresearch.com/cryptococcosis-market.html
“The key factor currently working for the growth of the global
cryptococcosis market is the growing count of patients being infected
by the disease. Although previously classified as a rarely occurring
illness, cryptococcosis is seen to be growing in count across the
globe and the healthcare industry is aware of this. The CDC had
stated earlier that close to a million new cases of cryptococcosis
are being spotted globally each year and are the cause of 625,000
deaths. The current gold standard for cryptococcosis treatment –
Amphotericin B plus oral flucytosin – is at the forefront of the
demand so far. The scope for other existing and pipeline treatments
is also very high,” states a TMR analyst.
Aiding the growth rate of the global cryptococcosis market are
multiple governments highly interested in eradicating the disease
from their nations. The increasingly powerful efforts put in by
governments are allowing players in the market to invest better into
advanced treatment options and the development on pipeline drugs, as
well as the better distribution of existing ones. The count of
cryptococcosis patients is also directly linked to the diagnosis of
HIV, which is another growing count in the world. The increasing
number of HIV patients are shown to be highly likely to develop
cryptococcosis during late-stage HIV infection, further pushing the
demand for cryptococcosis treatment.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14984
One of the key factors holding the global cryptococcosis market back
currently is the very high mortality rate among cryptococcosis
patients. Pneumocystis pneumonia and cryptococcal meningitis are the
two greater fungal infections that lead to death in the world. The
mortality rate of HIV patients who get diagnosed with cryptococcosis
is extremely close to 100%. This gives a very minor scope of
development of existing and pipeline drugs as it can cripple the
overall testing phase. The market is also expected to face severe
degradation of quality due to the imminent patent expirations and the
consequent surge of generics. Their extremely low pricing will allow
them to take up large demand volumes in all regions, disallowing
branded manufacturers from generating enough to invest in further
research and development.
“The future of the global cryptococcosis market can lie in the
installation of integrated facilities in the regions where
penetration potential is currently at an all-time high. These
integrated facilities can allow manufacturers in the pharmaceutical
industry to reduce operating costs and increase production speeds,
allowing them to maintain a competitive edge against rivals,” adds
the analyst.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=14984
The highly fragmented global cryptococcosis market is being pioneered
by only a handful of players based in developed regions of the world.
Pfizer, Inc., Valeant Pharmaceuticals, Inc., Bristol-Myers Squibb
Company, and Janssen Biotech, Inc. had collectively held a share of
41% in the global cryptococcosis market in terms of value, for 2015.
Their dominance in the market was marked by factors such as operating
stronghold in developed economies where the demand and awareness are
high, better brand name recognition, and higher investments in
research and development.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment